Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Breccia

Showing results (21-30 of 427) with videos related to

Pageof 43
Sort By:
Expert Opinion on Drug Safety|August 21, 2010
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their developmentMassimo Breccia, Giuliana Alimena
Expert Opinion on Pharmacotherapy|July 5, 2011
The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard doseMassimo Breccia, Giuliana Alimena
Cancers|November 13, 2025
Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative NeoplasmsAlessandro Costa, Massimo Breccia
British Journal of Haematology|December 27, 2023
How to improve treatment-free remission eligibility in chronic myeloid leukaemia?Alessandro Costa, Massimo Breccia
Oncotargets and Therapy|December 4, 2010
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinibMassimo Breccia, Giuliana Alimena
Critical Reviews in Oncology/Hematology|August 6, 2010
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib eraMassimo Breccia, Giuliana Alimena
Cancer Letters|February 11, 2014
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2025
SOHO State of the Art Updates and Next Questions: Combination Therapy in Chronic Myeloid Leukemia in Chronic PhaseAlessandro Costa, Massimo Breccia
Drugs & Aging|April 26, 2013
Management options for refractory chronic myeloid leukemia: considerations for the elderlyMassimo Breccia, Giuliana Alimena
Current Oncology Reports|March 8, 2018
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid LeukemiaMassimo Breccia, Robin Foà
Pageof 43

Showing results (21-30 of 427) with videos related to

Sort By:
Pageof 43
Expert Opinion on Drug Safety|August 21, 2010
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their developmentMassimo Breccia, Giuliana Alimena
Expert Opinion on Pharmacotherapy|July 5, 2011
The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard doseMassimo Breccia, Giuliana Alimena
Cancers|November 13, 2025
Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative NeoplasmsAlessandro Costa, Massimo Breccia
British Journal of Haematology|December 27, 2023
How to improve treatment-free remission eligibility in chronic myeloid leukaemia?Alessandro Costa, Massimo Breccia
Oncotargets and Therapy|December 4, 2010
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinibMassimo Breccia, Giuliana Alimena
Critical Reviews in Oncology/Hematology|August 6, 2010
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib eraMassimo Breccia, Giuliana Alimena
Cancer Letters|February 11, 2014
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemiaMassimo Breccia, Giuliana Alimena
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2025
SOHO State of the Art Updates and Next Questions: Combination Therapy in Chronic Myeloid Leukemia in Chronic PhaseAlessandro Costa, Massimo Breccia
Drugs & Aging|April 26, 2013
Management options for refractory chronic myeloid leukemia: considerations for the elderlyMassimo Breccia, Giuliana Alimena
Current Oncology Reports|March 8, 2018
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid LeukemiaMassimo Breccia, Robin Foà
Pageof 43